Dr. C. Michael Gibson, M.S., M.D., is an interventional cardiologist, researcher, and educator, serving as CEO of the non-profit Baim and PERFUSE research institutes at Harvard Medical School, which have conducted over 1,000 studies, published 5,500 papers, and led 100 FDA submissions. Consistently ranked among the world’s most highly cited authors since 2014, he has led large-scale clinical trials resulting in the global approval of drugs such as prasugrel, rivaroxaban, betrixaban, and andexanet, as well as devices for heart attack detection. He developed widely used measures of coronary blood flow (TIMI frame count and TIMI myocardial perfusion grade), held multiple leadership positions at Harvard-affiliated hospitals, founded platforms like WikiDoc and ClinicalTrialResults.org, conducted thousands of interviews, and is a prominent digital influencer, as well as a professional photographer and painter.
